The Health 202: The era of bipartisan work on lowering drug prices might be over
The Health 202: The era of bipartisan work on lowering drug prices might be over Paige Winfield Cunningham with Alexandra Ellerbeck Dare we say it: The window for bipartisan work on drug pricing reform may be closed. Sen. Ron Wyden, top Democrat on the powerful Senate Finance Committee, is focusing on a wish-list item for Democrats but poison pill for the GOP: eliminating a ban on the federal government using its negotiating power to directly force lower drug prices under Medicare. “I think we’ve got to take bold action on prescription drug prices,” Wyden (Ore.) ...